Suven Life Sciences granted patents for neurodegenerative drug Suven Life Sciences granted patents for neurodegenerative drug 
Pharmaceutical firm Suven Life Sciences has been granted three product patents &#8212; one each by South Korea, China and Canada &#8212; for drug used in the treatment of neurodegenerative diseases.


Neurodegenerative diseases include Alzheimer&#8217;s disease, Schizophrenia and Parkinson&#8217;s disease.


In a BSE filing the company said it has been granted &#8220;one product patent from South Korea, one product patent from China and one product patent from Canada corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases&#8220;.


These patents are valid through 2029, 2029 and 2031, respectively, the company said in a BSE filing.


Suven Life Sciences CEO Venkat Jasti said: &#8220;We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial need with huge market potential globally.&#8221;


With these new patents, Suven has a total of 14 granted patents from South Korea, 14 from China and 16 from Canada, respectively. 